Business Context and Reporting Period
Company: Akari Therapeutics, Plc
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2025
Reporting Period: Immediate event reporting regarding the closing of concurrent equity-related transactions.
The Company entered into a series of transactions to raise capital and reduce debt, including a Registered Direct Offering, a concurrent Private Placement, and a debt-for-equity exchange. The transactions are expected to close on or about December 17, 2025.
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Combined Proceeds & Liability Reduction | Approximately $9 million |
| Gross Cash Proceeds (Offerings) | Approximately $5 million |
| Debt Reduction (Note Exchange) | Approximately $4 million (principal) |
| Registered Direct Offering Price | $0.3883 per ADS (plus Series G Warrant) |
| Private Placement Price | $0.4041 per Pre-Funded Warrant (plus Series G Warrant) |
| Placement Agent Fees | 8.0% of gross proceeds + 0.5% management fee + up to $75,000 expense allowance |
Use of Proceeds: Continued research and development, working capital, and general corporate purposes.
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, or margins as this is a transactional report, not a periodic financial statement.
Material Changes Versus Prior Period
- Capital Structure: Significant dilution expected via the issuance of 10,043,774 ADSs in the Registered Direct Offering and 2,563,713 Pre-Funded Warrants in the Private Placement.
- Debt Reduction: Approximately $4 million in principal of unsecured promissory notes (2026 Notes) issued in August and September 2025 will be retired and exchanged for equity.
- Liquidity: Immediate increase in cash liquidity of approximately $5 million upon closing.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management intends to utilize the net proceeds to fund R&D and working capital. The Company has agreed to call a Special Meeting of shareholders within 75 days of the Closing Date to obtain approval for the issuance of ADSs underlying the warrants.
Risks and Contingencies
- Closing Conditions: The transactions are subject to customary closing conditions; failure to satisfy these may prevent the Offerings from closing.
- Shareholder Approval: Exercise of Series G Warrants and Note Exchange Warrants is contingent upon shareholder approval. If not obtained, the Company must hold meetings every 40 days until approval is secured or warrants expire.
- Lock-Up Provisions: The Company is restricted from issuing new equity or filing registration statements for 30 days post-closing and is barred from "variable rate transactions" for one year.
- Beneficial Ownership Limits: Warrant holders are restricted from exercising if it would cause them to beneficially own more than 4.99% (or 9.99% at election) of outstanding shares.
Important Facts for Investor Verification
- Verify the exact closing date (expected December 17, 2025) and confirmation of the $5 million cash receipt.
- Confirm the successful retirement of the $4 million in 2026 Notes and the issuance of corresponding Pre-Funded Warrants and Note Exchange Warrants.
- Monitor the scheduling of the Special Meeting for shareholder approval, required within 75 days of closing.
- Review the full text of the Purchase Agreements and Warrant terms filed as exhibits for specific anti-dilution adjustments and exercise restrictions.
- Assess the impact of the 8.5% total fee structure (plus expenses) on the net cash proceeds available for operations.